Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 1;325(5):C1244-C1251.
doi: 10.1152/ajpcell.00182.2023. Epub 2023 Sep 25.

Extracellular matrix contribution to disease progression and dysfunction in myopathy

Affiliations
Review

Extracellular matrix contribution to disease progression and dysfunction in myopathy

Ashlee M Long et al. Am J Physiol Cell Physiol. .

Abstract

Myopathic processes affect skeletal muscle and heart. In the muscular dystrophies, which are a subset of myopathies, muscle cells are gradually replaced by fibrosis and fat, impairing muscle function as well as regeneration and repair. In addition to skeletal muscle, these genetic disorders often also affect the heart, where fibrofatty infiltration progressively accumulates in the myocardium, impairing heart function. Although considerable effort has focused on gene-corrective and gene-replacement approaches to stabilize myofibers and cardiomyocytes, the continual and ongoing deposition of extracellular matrix itself contributes to tissue and organ dysfunction. Transcriptomic and proteomic profiling, along with high-resolution imaging and biophysical measurements, have been applied to define extracellular matrix components and their role in contributing to cardiac and skeletal muscle weakness. More recently, decellularization methods have been adapted to an on-slide format to preserve the spatial geography of the extracellular matrix, allowing new insight into matrix remodeling and its direct role in suppressing regeneration in muscle. This review highlights recent literature with focus on the extracellular matrix and molecular mechanisms that contribute to muscle and heart fibrotic disorders. We will also compare how the myopathic matrix differs from healthy matrix, emphasizing how the pathological matrix contributes to disease.

Keywords: acellular myoscaffolds; decellularization; fibrosis; heart; muscle.

PubMed Disclaimer

Conflict of interest statement

Northwestern University filed provisional patent nos. 62/783,619 and 63/309,925 on behalf of the authors (A.R.D. and E.M.M.). E.M.M. has served as a consultant for Amgen, AstraZeneca, Cytokinetics, Pfizer, PepGen, and Tenaya Therapeutics and is the founder of Ikaika Therapeutics. A.R.D. is CSO at Ikaika Therapeutics. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.

Figures

Figure 1.
Figure 1.
Sirius Red (collagen stain) demonstrates areas of fibrosis in gastrocnemius, diaphragm, and heart sections from dystrophin-deficient mdx mice, which serve as a model of Duchenne Muscular Dystrophy. The boxed area highlights a region of relatively intact muscle adjacent to regions of intense fibrosis (arrows). The diaphragm muscle is the most fibrotic muscle in this mouse model.
Figure 2.
Figure 2.
Schematic of the extracellular matrix and matrisome components important for muscle injury and repair. In skeletal muscle, acute injury leads to acute remodeling of the ECM, which can often fully resolve depending on the extent of the primary insult. In contrast, muscular dystrophy is characterized by ongoing degeneration concomitant with regeneration, which leads to progressive replacement of the myofibers by ECM. Figure created with BioRender.com. ECM, extra-cellular matrix.
Figure 3.
Figure 3.
Diagram of the on-slide decellularization process for studying the ECM and its potential downstream applications. Figure created with BioRender.com. ECM, extracellular matrix.

References

    1. Dowling JJ, Weihl CC, Spencer MJ. Molecular and cellular basis of genetically inherited skeletal muscle disorders. Nat Rev Mol Cell Biol 22: 713–732, 2021. doi:10.1038/s41580-021-00389-z. - DOI - PMC - PubMed
    1. Rando TA. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24: 1575–1594, 2001. doi:10.1002/mus.1192. - DOI - PubMed
    1. Angelini C. LGMD. Identification, description and classification. Acta Myol 39: 207–217, 2020. doi:10.36185/2532-1900-024. - DOI - PMC - PubMed
    1. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers 7: 13, 2021. doi:10.1038/s41572-021-00248-3. - DOI - PMC - PubMed
    1. Meyers TA, Townsend D. Cardiac pathophysiology and the future of cardiac therapies in duchenne muscular dystrophy. Int J Mol Sci 20: 4098, 2019. doi:10.3390/ijms20174098. - DOI - PMC - PubMed

Publication types